Business News • PR NewsWire • Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis

Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis

Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis

TARRYTOWN, N.Y. and PARIS, Sept. 15, 2018 /PRNewswire/ -- Results on skin clearing, itch and certain quality of life measurements were presented today as a late-breaking oral presentation at the 27th EADV Congress Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented...

View More : https://www.prnewswire.com:443/news-releases/positive-phase-3-results-presented-for-dupixent-dupilumab-show-significant-...

Releted News by prnewswire

DocuSign Announces Pricing of Follow-On Offering by Selling Stockholders

Adrealm Foundation joined by NYU, Carnegie Mellon scholars

Jolywood gana el premio de innovación tecnológica en AsiaSolar 2018

Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis

China Mobile Develops Roadside Units for LTE-V2X PC5 Direct Communication Featuring Qualcomm C-V2X Chipset Solution